Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes

✍ Scribed by Saburo Sone; Priti Tandon; Teruhiro Utsugi; Mitsumasa Ogawara; Eiji Shimizu; Akihiko Nii; Takeshi Ogura

• Publisher: John Wiley and Sons
• Year: 1986
• Tongue: French
• Weight: 672 KB
• Volume: 38
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910380407

✦ Synopsis

Freshly isolated human peripheral blood monocytes from healthy volunteers are not cytotoxic to allogeneic A375 melanoma cells, but they were rendered turnoricidal by incubation in vitro with either liposomes containing 5 pglpmol phospholipid of muramyl tripeptide phosphatidylethanolamine (liposome-MTP-PE; optimal dose, 500 nmollml) or recombinant human interferon gamma (rlFN-y; optimal dose, 100 UI ml). A combination of sub-threshold concentrations of liposome-MTP-PE (50 nmol/ml) and rlFN-y (I or 10 UI ml) also induced significant tumor-cell killing, indicating that the effects of rlFN-y and liposome-MTP-PE in monocyte activation are synergistic. In contrast to rlFN-y, recombinant INF-a and IFN-fl had additive effects with liposome-MTP-PE in human monocyte activation. Since recombinant human IFN--y has a synergistic effect with liposome-MTP-PE in monocyte activation, unlike IFN-a or IFN-0. and liposome-MTP-PE as well as rlFN-y is available at standardized concentrations, this combination could be of clinical value in the treatment of disseminated malignant disease.